Appendix 4E and 2023 Annual Report
Filed with ASX · · 55 pages · English
Summary by 6ix AI
The report highlights a substantial increase in revenues from ordinary activities, while also noting a rise in losses attributable to the owners of the company. Additionally, the report emphasizes the company's strengthened financial position, supported by recent capital raises, which positions it well for future growth.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Prescient Therapeutics Limited on 6ix
Story so far
Earlier from Prescient Therapeutics
- June 2023 Quarterly Update and Appendix 4C
- March 2023 Quarterly Update and Appendix 4C
- Continued promising results in PTX-100 TCL trial
- FDA grants broader orphan drug status to PTX100 for TCLs
- December 2022 Quarterly Update and Appendix 4C
Later from Prescient Therapeutics
- September 2023 Quarterly Update and Appendix 4C
- PTX-100 Ph1b results show excellent safety & efficacy in TCL
- December 2023 Quarterly Update and Appendix 4C
- March 2024 Quarterly Update and Appendix 4C
- June 2024 Quarterly Update and Appendix 4C
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics